KRAS and colorectal carcinoma: In conclusion, our study describes for the first time two distinct models for KRAS- and BRAF-driven CRC where the HH-GLI and NOTCH signaling pathways play different roles in the chemoresistance and mesenchymal phenotype of CRC (Figure 6).